Zeaxanthin Encyclopedia — Scientific Background

What Is Zeaxanthin?

Zeaxanthin (CAS 144-68-3), also known as (3R,3′R)-β,β-carotene-3,3′-diol, is a naturally occurring xanthophyll carotenoid characterized by the molecular formula C₄₀H₅₆O₂ and a molecular weight of 568.87 g/mol. It is a member of the xanthophyll subclass of carotenoids, which are oxygenated derivatives of carotenes. Zeaxanthin is a yellow-orange pigment synthesized exclusively by plants and microorganisms; humans cannot synthesize it and must acquire it through dietary intake.

The Macular Pigment and Blue Light Filtration

Zeaxanthin and lutein are the only two dietary carotenoids selectively accumulated in the human macula, where they form the macular pigment. Zeaxanthin is concentrated in the fovea—the very center of the macula—while lutein predominates in the peripheral macula. This pigment serves as a natural optical filter, absorbing high-energy blue light (wavelengths 400–500 nm) before it reaches the photoreceptor cells. Macular pigment, composed solely of lutein and zeaxanthin, absorbs blue light prior to its reaching the underlying photoreceptor cell layer, protecting it from light and presumably oxidative damage. Increased ingestion of zeaxanthin and lutein has been reported to increase macular pigment density.

Mechanisms of Action

Antioxidant Defense

Zeaxanthin is a potent antioxidant that neutralizes reactive oxygen species (ROS) and reactive nitrogen species (RNS). Its extended conjugated double-bond system enables efficient scavenging of free radicals, and it protects cellular membranes from lipid peroxidation. The compound's antioxidant activity is particularly important in the retina, where high oxygen tension and constant light exposure generate significant oxidative stress.

Blue Light Filtration

The macular pigment formed by zeaxanthin and lutein acts as a short-wavelength light filter, reducing chromatic aberration and photic damage to the retina. This optical filtration function is complementary to zeaxanthin's antioxidant role, providing both physical and biochemical protection to the retina.

Anti-Inflammatory Effects

Zeaxanthin has demonstrated anti-inflammatory properties, modulating inflammatory pathways and reducing the production of pro-inflammatory cytokines in ocular and systemic tissues.

The Bioavailability Challenge

Despite its important physiological functions, native zeaxanthin presents significant bioavailability challenges. The compound is practically insoluble in water and only sparingly soluble in chloroform. Zeaxanthin generally exhibits low bioavailability due to its poor stability and solubility in aqueous media. Carotenoids are fat-soluble compounds and are absorbed like dietary fat, primarily by the mucosa of the small intestine via passive diffusion. Lutein absorption is generally low (estimated at 5–20% of an oral dose) and highly variable among individuals. Early human trials demonstrated that dietary matrices rich in phospholipids, such as egg yolk, avocado, or milk fat, produced higher plasma lutein/zeaxanthin responses than crystalline or beadlet supplement forms.

These limitations have driven the development of advanced delivery systems, including liposomes, nanoemulsions, and phospholipid-based carriers. Among these, liposomal encapsulation has emerged as one of the most effective strategies for enhancing zeaxanthin bioavailability.

Liposomal zeaxanthin

Liposomal encapsulation of zeaxanthin provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the zeaxanthin molecule, forming a nanoscale vesicle that enhances solubility, stability, and cellular uptake. This delivery system:

• Achieves a mean hydrodynamic diameter of 182.4 ± 4.1 nm with PDI of 0.212 ± 0.016

• Provides ζ-potential of −34.7 ± 1.8 mV, indicating excellent colloidal stability

• Delivers approximately 26% higher AUC₀–ₜ and 32% higher Cmax compared to MCT-only controls

• Protects zeaxanthin from light, heat, and oxidative degradation

• Reconstructs easily in water to form a stable nanoscale dispersion

The liposomal powder contains mainly zwitterionic phosphatidylcholine and a small amount of negatively charged phosphatidylglycerol, and reconstitutes easily in water to form a stable nanoscale dispersion. The pharmacokinetic study demonstrated that phosphatidylserine (PS) was the most effective vehicle among the four formulations tested, yielding approximately 26% higher AUC₀–ₜ and 32% higher Cmax than the MCT-only control.

Clinical Evidence

AREDS2 Clinical Trial

The Age-Related Eye Disease Study 2 (AREDS2) was a major randomized, double-masked, placebo-controlled, 2×2 factorial trial conducted by the National Eye Institute. The study enrolled 4,203 patients with intermediate or late AMD in one eye. Participants were randomized to receive lutein (10 mg) + zeaxanthin (2 mg), DHA (350 mg) + EPA (650 mg), lutein + zeaxanthin and DHA + EPA, or placebo. The study demonstrated an approximately 25% reduction in the risk of progression from intermediate to advanced AMD. Patients with the lowest baseline dietary carotenoid intake who received the supplement showed a 26% reduction in risk for AMD progression. Based on these findings, the NEI research authors recommend adding 10 mg lutein and 2 mg zeaxanthin and removing beta-carotene from the current dietary supplement formula.

Ocular Safety

A study in primates did not indicate any evidence of ocular toxicity or excessive accumulation with zeaxanthin consumption. A published study in ferrets provides limited support for the absence of any stimulating effect of zeaxanthin consumption on the incidence of lung cancer in heavy smokers.

Safety and Regulatory

Zeaxanthin is generally well tolerated. In 2006, JECFA defined a group ADI of 0–2 mg/kg body weight for lutein from Tagetes erecta and zeaxanthin (synthetic). In 2018, this group ADI was withdrawn, and the committee established a group ADI of "not specified" for lutein, lutein esters, and zeaxanthin (synthetic), considering these substances to be of low toxicity with no adverse effects observed in a broad range of toxicological studies in laboratory animals and clinical studies in humans.

The EFSA NDA Scientific Panel applied a 200-fold safety factor to a rat NOAEL of 150 mg/kg bw/day and defined an ADI of 0.75 mg/kg bw/day or 53 mg/day for a 70 kg adult. However, the EU in 2013 formally approved upper use levels of 2 mg/day as this was the use level proposed by the applicant. Information from human intervention studies also supports that an intake higher than 2 mg/day is safe, and an intake level of 20 mg/day for up to 6 months was without adverse effect.

In the United States, synthetic zeaxanthin is marketed since 2002 under Generally Recognized As Safe (GRAS) legislation, based on DSM safety studies, with use level in foods and beverages of 0.25 mg/serving. The FDA has received multiple GRAS notices for zeaxanthin from marigold extract, all of which received "no questions at this time" response letters.

Zeaxanthin is widely commercialized as a dietary supplement ingredient and food colorant. In the United States, it is Generally Recognized As Safe (GRAS) for use in food and dietary supplements. In Europe, it is authorized as a novel food ingredient. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

549$/KG

199$/KG

129$/KG